These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 35470744)

  • 21. Concomitant psoriasis and hidradenitis suppurativa responsive to adalimumab therapy: A case series.
    Yen CF; Huang YH; Chi CC
    Indian J Dermatol Venereol Leprol; 2021; 87(2):223-226. PubMed ID: 31389375
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lipid Alterations and Metabolism Disturbances in Selected Inflammatory Skin Diseases.
    Nowowiejska J; Baran A; Flisiak I
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108216
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Case report: Treating a co-existence of hidradenitis suppurativa and psoriasis with different therapeutic approaches.
    Tampouratzi E; Kanni T; Katsantonis J; Douvali T
    F1000Res; 2019; 8():2002. PubMed ID: 33456757
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adalimumab (antitumour necrosis factor-α) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study.
    van der Zee HH; Laman JD; de Ruiter L; Dik WA; Prens EP
    Br J Dermatol; 2012 Feb; 166(2):298-305. PubMed ID: 22013960
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The anti-inflammatory potency of biologics targeting tumour necrosis factor-α, interleukin (IL)-17A, IL-12/23 and CD20 in hidradenitis suppurativa: an ex vivo study.
    Vossen ARJV; Ardon CB; van der Zee HH; Lubberts E; Prens EP
    Br J Dermatol; 2019 Aug; 181(2):314-323. PubMed ID: 30657173
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Practical Guide to Using Biologics in Pediatric Dermatology.
    George A; Lansang RP; Lansang P; Gooderham M
    J Cutan Med Surg; 2024; 28(1):59-67. PubMed ID: 38229411
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β.
    van der Zee HH; de Ruiter L; van den Broecke DG; Dik WA; Laman JD; Prens EP
    Br J Dermatol; 2011 Jun; 164(6):1292-8. PubMed ID: 21332464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. "Inflammatory skin march" in atopic dermatitis and psoriasis.
    Furue M; Kadono T
    Inflamm Res; 2017 Oct; 66(10):833-842. PubMed ID: 28620798
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New and Emerging Treatments for Generalized Pustular Psoriasis: Focus on IL-36 Receptor Inhibitors.
    Vilaça J; Yilmaz O; Torres T
    Pharmaceutics; 2024 Jul; 16(7):. PubMed ID: 39065604
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pustular Psoriasis: A Narrative Review of Recent Developments in Pathophysiology and Therapeutic Options.
    Menter A; Van Voorhees AS; Hsu S
    Dermatol Ther (Heidelb); 2021 Dec; 11(6):1917-1929. PubMed ID: 34626330
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inflammation: A Contributor to Depressive Comorbidity in Inflammatory Skin Disease.
    Farzanfar D; Dowlati Y; French LE; Lowes MA; Alavi A
    Skin Pharmacol Physiol; 2018; 31(5):246-251. PubMed ID: 29953999
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunobiologicals in dermatology.
    Silva DLFD; Secamilli EN; Beleli MV; Massuda JY; Franca AFEC; Magalhães RF
    An Bras Dermatol; 2022; 97(3):275-283. PubMed ID: 35314083
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Updates on treatment guidelines for psoriasis, atopic dermatitis (eczema), hidradenitis suppurativa, and acne/rosacea during the COVID-19 pandemic.
    Yim RM; Singh I; Armstrong AW
    Dermatol Online J; 2020 Oct; 26(10):. PubMed ID: 33147660
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interleukin-36 in hidradenitis suppurativa: evidence for a distinctive proinflammatory role and a key factor in the development of an inflammatory loop.
    Hessam S; Sand M; Gambichler T; Skrygan M; Rüddel I; Bechara FG
    Br J Dermatol; 2018 Mar; 178(3):761-767. PubMed ID: 28975626
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Primary alterations during the development of hidradenitis suppurativa.
    Dajnoki Z; Somogyi O; Medgyesi B; Jenei A; Szabó L; Gáspár K; Hendrik Z; Gergely P; Imre D; Póliska S; Törőcsik D; Zouboulis CC; Prens EP; Kapitány A; Szegedi A
    J Eur Acad Dermatol Venereol; 2022 Mar; 36(3):462-471. PubMed ID: 34724272
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolic syndrome and inflammatory skin conditions.
    Steele CE; Morrell D; Evans M
    Curr Opin Pediatr; 2019 Aug; 31(4):515-522. PubMed ID: 31169544
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of Ketogenic and Low-Glycemic Diets on Inflammatory Skin Conditions.
    Roster K; Xie L; Nguyen T; Lipner SR
    Cutis; 2024 Feb; 113(2):75-80. PubMed ID: 38593092
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biologics for chronic inflammatory skin diseases: an update for the clinician.
    Yao Y; Ravn Jørgensen AH; Thomsen SF
    J Dermatolog Treat; 2020 Mar; 31(2):108-130. PubMed ID: 30827126
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Generalized pustular psoriasis: the new era of treatment with IL-36 receptor inhibitors.
    Maçães CO; Lé AM; Torres T
    J Dermatolog Treat; 2022 Nov; 33(7):2911-2918. PubMed ID: 35695278
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa.
    Kelly G; Hughes R; McGarry T; van den Born M; Adamzik K; Fitzgerald R; Lawlor C; Tobin AM; Sweeney CM; Kirby B
    Br J Dermatol; 2015 Dec; 173(6):1431-9. PubMed ID: 26282467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.